

ANNUAL Snapshot

(NHI price base)

April 2024 to March 2025

Date of Release 2025.4.28




Monitoring Pharmaceutical Industry for the Society

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2025 Encise Inc. All Rights Reserved.

Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

Period at Glance (% Growth YoY)




Sales figures are rounded to the nearest ¥Billion.

Source: Encise Inc.

Quarterly & Annual Sales of FY 2024 Quarterly & Annual Sales of FY 2023


We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2025 Encise Inc. All Rights Reserved.



Source: Encise Inc.


^{*} Products including coronavirus disease 2019 (COVID-19)-related drugs and regenerative medicine products have not been considered.



We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2025 Encise Inc. All Rights Reserved.

Top-10 Therapeutic Classes*



Source: Encise Inc.


We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2025 Encise Inc. All Rights Reserved.

^{*} Products including coronavirus disease 2019 (COVID-19)-related drugs and regenerative medicine products have not been considered.

Top 20 Companies**





Source: Encise Inc.

* Products including coronavirus disease 2019 (COVID-19)-related drugs and regenerative medicine products have not been considered.

** Marketing Authorization Holders

Japanese Companies
Foreign Companies

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2025 Encise Inc. All Rights Reserved.

Memo

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2025 Encise Inc. All Rights Reserved.



Terms of Use

Therapeutic Classes are based on Encise's original classification.

Encise Research Center has prepared this Report by processing, editing, and developing estimates based on the ethical drug information Encise has collected. Encise does not guarantee the accuracy, completeness, comprehensiveness, fitness for purpose, and currentness of the information in this Report, or that it meets any specific threshold in terms of content and/or quality.

Encise and Encise Research Center assume no responsibility for any damage or disadvantage whatsoever caused by the use of this information.

Unless otherwise indicated, all of the content of the Report is owned by Encise, and Encise reserves all the rights including, but not limited to, copyrights contained or expressed in or relating to the Report, and they are protected by applicable laws. No one, except with and to the extent of the prior written consent of Encise, shall transfer the Report to any person or let any person use the Report, or quote, reproduce or copy any and all part of the Report.

Encise Research Center

MFPR Shibuya bldg., 2-5, Shibuya 1-chome, Shibuya-ku, Tokyo 150-0002, Japan Phone: +81-3-6712-6339 Fax: +81-3-6712-6343

Encise Research Center | Research Report | Copyright © 2025 Encise Inc. All Rights Reserved.

Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.